Q2 2023 Earnings Estimate for Alimera Sciences, Inc. Issued By HC Wainwright (NASDAQ:ALIM)

Posted by Defense World Staff on May 19th, 2023

Alimera Sciences, Inc. (NASDAQ:ALIM – Get Rating) – Stock analysts at HC Wainwright increased their Q2 2023 earnings estimates for Alimera Sciences in a research note issued to investors on Tuesday, May 16th. HC Wainwright analyst Y. Chen now forecasts that the biopharmaceutical company will post earnings of ($0.22) per share for the quarter, up from their prior forecast of ($0.30). HC Wainwright currently has a “Buy” rating and a $9.00 target price on the stock. The consensus estimate for Alimera Sciences’ current full-year earnings is ($1.08) per share. HC Wainwright also issued estimates for Alimera Sciences’ Q3 2023 earnings at ($0.19) EPS, Q4 2023 earnings at ($0.10) EPS and FY2023 earnings at ($1.19) EPS.

Several other research analysts have also weighed in on ALIM. StockNews.com assumed coverage on Alimera Sciences in a research report on Tuesday. They set a “hold” rating on the stock. Craig Hallum dropped their price target on shares of Alimera Sciences from $18.00 to $8.00 in a research report on Monday, April 3rd.

Alimera Sciences Stock Performance

NASDAQ:ALIM opened at $2.46 on Thursday. Alimera Sciences has a 52-week low of $1.30 and a 52-week high of $7.92. The company has a market cap of $18.20 million, a P/E ratio of -1.00 and a beta of 1.38. The stock’s 50-day simple moving average is $1.86 and its 200 day simple moving average is $2.65.

Institutional Investors Weigh In On Alimera Sciences

A number of institutional investors have recently made changes to their positions in the company. Millennium Management LLC acquired a new stake in Alimera Sciences during the 4th quarter worth approximately $32,000. Susquehanna International Group LLP acquired a new stake in shares of Alimera Sciences during the fourth quarter worth $92,000. Renaissance Technologies LLC boosted its position in shares of Alimera Sciences by 2.3% in the second quarter. Renaissance Technologies LLC now owns 127,693 shares of the biopharmaceutical company’s stock valued at $698,000 after acquiring an additional 2,900 shares during the period. Finally, Caligan Partners LP acquired a new position in shares of Alimera Sciences in the fourth quarter valued at about $1,297,000. Institutional investors own 24.58% of the company’s stock.

Insider Buying and Selling

In other Alimera Sciences news, major shareholder Alto Investors Lp Palo sold 200,919 shares of Alimera Sciences stock in a transaction on Friday, March 24th. The shares were sold at an average price of $1.56, for a total transaction of $313,433.64. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 12.90% of the stock is owned by insiders.

Alimera Sciences Company Profile

(Get Rating)

Alimera Sciences, Inc engages in the research and development of biopharmaceutical products. It operates through the following geographical segments: U.S. and International. The firm focuses on the development of ophthalmic pharmaceuticals for the treatment of diabetic macular edema, wet and dry age-related macular degeneration and retinal vein occlusion.